Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated
Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.
Harmony Biosciences Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 145 | $5,425.91 | $5,555.67 | $129.76 | 2.39% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 21,108 | $705,640.44 | $810,758.28 | $105,117.84 | 14.9% |
| AF Anthony Fasano Clark Estates INC/NY | 81,300 | $2.58M | $3.12M | $530,281.5 | 20.52% |
| BG Bart Gancher Intech Investment Management LLC | 75,851 | $2.24M | $2.91M | $672,177.06 | 29.99% |
| JM John Malone Amundi | 16,131 | $532,557.54 | $629,109 | $96,551.46 | 18.13% |
Harmony Biosciences Holdings, Inc. (HRMY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Harmony Biosciences Holdings, Inc. ever had a stock split?
Harmony Biosciences Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey Dayno CEO | NASDAQ (NMS) Exchange | 413197104 CUSIP |
| US Country | 293 Employees | - Last Dividend | - Last Split | 19 Aug 2020 IPO Date |
Overview
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company dedicated to the development and commercialization of unique therapies for patients suffering from rare and other neurological diseases within the United States. Initially known as Harmony Biosciences II, Inc., the company underwent a name change to Harmony Biosciences Holdings, Inc. in February 2020. Founded in 2017, Harmony Biosciences has established its headquarters in Plymouth Meeting, Pennsylvania, signifying its commitment to addressing unmet medical needs in the neurology space through innovative research and therapeutic solutions.
Products and Services
- WAKIX (pitolisant)
- HBS-102
Harmony Biosciences offers WAKIX (pitolisant), which is a pioneering molecule known for its novel mechanism of action. It is specifically designed for the treatment of excessive daytime sleepiness in adult patients suffering from narcolepsy. This product marks a significant advancement in narcolepsy treatment, offering a new hope and improved quality of life for patients grappling with this chronic sleep disorder.
Another significant therapeutic solution in Harmony Biosciences' portfolio is HBS-102, which targets the melanin-concentrating hormone receptor 1 for MCH neurons. This product represents the company's ongoing commitment to exploring new pathways and mechanisms to address neurological disorders with unmet medical needs. While still under development, HBS-102 underscores Harmony Biosciences’ dedication to expanding its offerings and making impactful contributions to the field of neurology.
